Management of pregnancy in systemic lupus erythematosus

Systemic lupus erythematosus (SLE) is an autoantibody-mediated systemic autoimmune disease, predominantly affecting young females. Pregnancy is increasingly common in the setting of SLE, as survival and quality of life of patients improve. Although live births can be achieved in the most cases, pregnancy in patients with SLE remains a high-risk condition. Maternal and fetal mortality and morbidity are considerably increased, compared with the general population. Aberrations in pregnancy-related maternal immune adaptations are likely contributors. Active maternal disease, renal involvement, specific autoantibody subsets and advanced organ damage are predictors of poor outcome. Therapeutic options are limited during pregnancy as maternal benefit has to be weighed against fetal risk. Prevention of preterm birth and refractory pregnancy loss, as well as management of established neonatal heart block remain unmet needs. Further research should address these important issues that affect young patients with SLE and their babies.

[1]  F. Kirkham,et al.  Antithrombotic therapy in neonates and children: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). , 2008, Chest.

[2]  E. Herlenius,et al.  Ro/SSA autoantibodies directly bind cardiomyocytes, disturb calcium homeostasis, and mediate congenital heart block , 2005, The Journal of experimental medicine.

[3]  D. Mevorach,et al.  Prevention of complete heart block in children of mothers with anti-SSA/Ro and anti-SSB/La autoantibodies: detection and treatment of first-degree atrioventricular block , 2009, Current opinion in rheumatology.

[4]  J. Salmon,et al.  Heparin prevents antiphospholipid antibody–induced fetal loss by inhibiting complement activation , 2004, Nature Medicine.

[5]  D. El‐Haieg,et al.  Plasmapheresis and pregnancy outcome in patients with antiphospholipid syndrome , 2007, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[6]  M. Vilardell‐Tarrés,et al.  Clinical predictors of fetal and maternal outcome in systemic lupus erythematosus: a prospective study of 103 pregnancies. , 2002, Rheumatology.

[7]  D. Wlody,et al.  Hypertension in pregnancy. , 1992, The New England journal of medicine.

[8]  Mimi Y. Kim,et al.  Cutaneous manifestations of neonatal lupus and risk of subsequent congenital heart block. , 2010, Arthritis and rheumatism.

[9]  Y. El‐Sayed,et al.  A multicenter, placebo-controlled pilot study of intravenous immune globulin treatment of antiphospholipid syndrome during pregnancy. The Pregnancy Loss Study Group. , 2000, American journal of obstetrics and gynecology.

[10]  J. Piette,et al.  The second trimester Doppler ultrasound examination is the best predictor of late pregnancy outcome in systemic lupus erythematosus and/or the antiphospholipid syndrome. , 2006, Rheumatology.

[11]  K. Takakuwa,et al.  Prospective Studies of the Association Between Anticardiolipin Antibody and Outcome of Pregnancy , 1995, Obstetrics and gynecology.

[12]  S. le Cessie,et al.  Classical complement activation as a footprint for murine and human antiphospholipid antibody‐induced fetal loss , 2011, The Journal of pathology.

[13]  S. Taler,et al.  ASH Position Paper: Hypertension in Pregnancy , 2009, Journal of clinical hypertension.

[14]  W. Frishman,et al.  Beta-adrenergic receptor blockers. Adverse effects and drug interactions. , 1988, Hypertension.

[15]  F. Perlík [Adverse effects and drug interactions]. , 2004, Casopis lekaru ceskych.

[16]  A. Piccoli,et al.  Steroid hormones and disease activity during pregnancy in systemic lupus erythematosus. , 2002, Arthritis and rheumatism.

[17]  S. Bewley,et al.  Pregnancy Outcomes in Systemic Lupus Erythematosus with and without Previous Nephritis , 2011, The Journal of Rheumatology.

[18]  M. Cheung,et al.  Combination of heparin and aspirin is superior to aspirin alone in enhancing live births in patients with recurrent pregnancy loss and positive anti-phospholipid antibodies: a meta-analysis of randomized controlled trials and meta-regression. , 2010, Rheumatology.

[19]  J. Craig,et al.  Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant. , 2005, The Cochrane database of systematic reviews.

[20]  L. Tam,et al.  Predictors of maternal and fetal outcomes in pregnancies of patients with systemic lupus erythematosus , 2011, Lupus.

[21]  Mimi Y. Kim,et al.  Recurrence rates of cardiac manifestations associated with neonatal lupus and maternal/fetal risk factors. , 2009, Arthritis and rheumatism.

[22]  G. Girardi Role of Tissue Factor in the Maternal Immunological Attack of the Embryo in the Antiphospholipid Syndrome , 2010, Clinical reviews in allergy & immunology.

[23]  K. Kalunian,et al.  Assessing disease activity in SLE patients during pregnancy , 1999, Lupus.

[24]  L. Magder,et al.  The impact of increased lupus activity on obstetric outcomes. , 2005, Arthritis and rheumatism.

[25]  C. Vasconcelos,et al.  Pregnancy and Systemic Lupus Erythematosus: Review of Clinical Features and Outcome of 51 Pregnancies at a Single Institution , 2010, Clinical reviews in allergy & immunology.

[26]  G. Koren,et al.  Use of warfarin during pregnancy. , 2002, Canadian family physician Medecin de famille canadien.

[27]  L. Hornberger,et al.  Spectrum of Cardiac Involvement in Neonatal Lupus , 2010, Scandinavian journal of immunology.

[28]  D. Marcelli,et al.  Pregnancy in women with pre-existing lupus nephritis: predictors of fetal and maternal outcome. , 2008, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[29]  J. Hirsh,et al.  Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). , 2008, Chest.

[30]  K. Kuczkowski Clopidogrel and pregnancy: a situation pregnant with danger? , 2009, Archives of Gynecology and Obstetrics.

[31]  A. Ferrante,et al.  Randomized study of subcutaneous low molecular weight heparin plus aspirin versus intravenous immunoglobulin in the treatment of recurrent fetal loss associated with antiphospholipid antibodies. , 2003, Arthritis and rheumatism.

[32]  Mimi Y. Kim,et al.  Prospective evaluation of fetuses with autoimmune-associated congenital heart block followed in the PR Interval and Dexamethasone Evaluation (PRIDE) Study. , 2009, The American journal of cardiology.

[33]  A. Einarson,et al.  Use of diuretics during pregnancy. , 2009, Canadian family physician Medecin de famille canadien.

[34]  J. Piette,et al.  Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patients , 2008, Annals of the rheumatic diseases.

[35]  S. Sonesson Diagnosing Foetal Atrioventricular Heart Blocks , 2010, Scandinavian journal of immunology.

[36]  Y. Shoenfeld,et al.  International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) , 2006, Journal of thrombosis and haemostasis : JTH.

[37]  M. Shaarawy,et al.  Effects of the long-term use of depot medroxyprogesterone acetate as hormonal contraceptive on bone mineral density and biochemical markers of bone remodeling. , 2006, Contraception.

[38]  Mimi Y. Kim,et al.  Evaluation of the risk of anti-SSA/Ro-SSB/La antibody-associated cardiac manifestations of neonatal lupus in fetuses of mothers with systemic lupus erythematosus exposed to hydroxychloroquine , 2010, Annals of the rheumatic diseases.

[39]  J. Atkinson,et al.  Mutations in Complement Regulatory Proteins Predispose to Preeclampsia: A Genetic Analysis of the PROMISSE Cohort , 2011, PLoS medicine.

[40]  P. Stoutenbeek,et al.  Treatment of fetal heart block with maternal steroid therapy: case report and review of the literature , 2004, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

[41]  F. Di Nicuolo,et al.  Pathogenic role of anti-beta2-glycoprotein I antibodies on human placenta: functional effects related to implantation and roles of heparin. , 2007, Human reproduction update.

[42]  J. Salmon,et al.  Antiphospholipid antibodies and pregnancy loss: a disorder of inflammation. , 2008, Journal of reproductive immunology.

[43]  L. Trupin,et al.  Brief index of lupus damage: A patient‐reported measure of damage in systemic lupus erythematosus , 2011, Arthritis care & research.

[44]  D. Gladman,et al.  The Effect of Lupus Nephritis on Pregnancy Outcome and Fetal and Maternal Complications , 2010, The Journal of Rheumatology.

[45]  D. Friedman,et al.  Comparison of treatment with fluorinated glucocorticoids to the natural history of autoantibody-associated congenital heart block: retrospective review of the research registry for neonatal lupus. , 1999, Arthritis and rheumatism.

[46]  M. Petri,et al.  Soluble Fms-like tyrosine kinase associated with preeclampsia in pregnancy in systemic lupus erythematosus. , 2008, The Journal of rheumatology.

[47]  M. Petri,et al.  Hopkins Lupus Pregnancy Center: 1987 to 1996. , 1997, Rheumatic diseases clinics of North America.

[48]  E. L. Chia,et al.  Cardiac time intervals of normal fetuses using noninvasive fetal electrocardiography , 2005, Prenatal diagnosis.

[49]  Aeilko H. Zwinderman,et al.  Use of uterine artery Doppler ultrasonography to predict pre-eclampsia and intrauterine growth restriction: a systematic review and bivariable meta-analysis , 2008, Canadian Medical Association Journal.

[50]  F. Schmidt Meta-Analysis , 2008 .

[51]  P. Maccallum,et al.  Antenatal screening for pre-eclampsia: Evaluation of the NICE and pre-eclampsia community guidelines , 2012, Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology.

[52]  Abdulrahman Al-Nabti,et al.  Drug-eluting stent implantation for acute myocardial infarction during pregnancy with use of glycoprotein IIb/IIIa inhibitor, aspirin and clopidogrel. , 2008, The Journal of invasive cardiology.

[53]  W. Weston,et al.  Cutaneous lupus erythematosus during the neonatal and childhood periods , 1997, Lupus.

[54]  M. Petri,et al.  Disassociation of sex hormone levels and cytokine production in SLE patients , 2001, Lupus.

[55]  C. Kimmel,et al.  Adverse pregnancy outcomes associated with maternal enalapril antihypertensive treatment , 2003, Pharmacoepidemiology and drug safety.

[56]  L. Hornberger,et al.  Increased risk of complete congenital heart block in infants born to women with hypothyroidism and anti-Ro and/or anti-La antibodies. , 2006, The Journal of rheumatology.

[57]  I. Stathopoulos,et al.  The use of bisphosphonates in women prior to or during pregnancy and lactation. , 2011, Hormones.

[58]  D. Friedman,et al.  Cardiac manifestations of neonatal lupus erythematosus: guidelines to management, integrating clues from the bench and bedside , 2009, Nature Clinical Practice Rheumatology.

[59]  E. Myers,et al.  A national study of the complications of lupus in pregnancy. , 2008, American journal of obstetrics and gynecology.

[60]  C. Laskin,et al.  Decrease in pregnancy loss rates in patients with systemic lupus erythematosus over a 40-year period. , 2005, The Journal of rheumatology.

[61]  B. Tura,et al.  Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study , 2001, Lupus.

[62]  M. Petri,et al.  Effect of pregnancy on serum cytokines in SLE patients , 2012, Arthritis Research & Therapy.

[63]  A Tincani,et al.  Failure of intravenous immunoglobulin to prevent congenital heart block: Findings of a multicenter, prospective, observational study. , 2010, Arthritis and rheumatism.

[64]  E. Chakravarty,et al.  Obstetric hospitalizations in the United States for women with systemic lupus erythematosus and rheumatoid arthritis. , 2006, Arthritis and rheumatism.

[65]  P. Bossuyt,et al.  Accuracy of Circulating Placental Growth Factor, Vascular Endothelial Growth Factor, Soluble fms-like Tyrosine Kinase-1, and Soluble Endoglin in the Prediction of Preeclampsia: A Systematic Review and Meta-Analysis , 2013 .

[66]  Mimi Y. Kim,et al.  Combined oral contraceptives in women with systemic lupus erythematosus. , 2005, The New England journal of medicine.

[67]  M. Genovese,et al.  Factors that predict prematurity and preeclampsia in pregnancies that are complicated by systemic lupus erythematosus. , 2005, American journal of obstetrics and gynecology.

[68]  L. Magder,et al.  Thyroid disease in pregnant women with systemic lupus erythematosus: increased preterm delivery , 2011, Lupus.

[69]  J. Buyon,et al.  Cutaneous manifestations of neonatal lupus without heart block: characteristics of mothers and children enrolled in a national registry. , 2000, The Journal of pediatrics.

[70]  E. Makrakis,et al.  Low‐molecular‐weight heparin versus intravenous immunoglobulin for recurrent abortion associated with antiphospholipid antibody syndrome , 2009, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[71]  C. Gordon,et al.  Measuring systemic lupus erythematosus activity during pregnancy: validation of the lupus activity index in pregnancy scale. , 2004, Arthritis and rheumatism.

[72]  I. Bruce,et al.  SLE and pregnancy: the potential role for regulatory T cells , 2011, Nature Reviews Rheumatology.

[73]  C. Gordon,et al.  Anti-inflammatory and immunosuppressive drugs and reproduction , 2006, Arthritis research & therapy.

[74]  Kent R Bailey,et al.  A systematic review and meta-analysis of pregnancy outcomes in patients with systemic lupus erythematosus and lupus nephritis. , 2010, Clinical journal of the American Society of Nephrology : CJASN.

[75]  L. Magder,et al.  Early Risk Factors for Pregnancy Loss in Lupus , 2006, Obstetrics and gynecology.

[76]  E. Jaeggi,et al.  The Benefits of Transplacental Treatment of Isolated Congenital Complete Heart Block Associated with Maternal Anti‐Ro / SSA Antibodies: A Review , 2010, Scandinavian journal of immunology.

[77]  R. Xu,et al.  Birth outcomes in women who have taken leflunomide during pregnancy. , 2010, Arthritis and rheumatism.

[78]  N. Field,et al.  Pregnancy outcomes in women with systemic lupus erythematosus , 2001, The Journal of maternal-fetal medicine.

[79]  S. Hernández-Díaz,et al.  Major congenital malformations after first-trimester exposure to ACE inhibitors. , 2006, The New England journal of medicine.

[80]  D. Back,et al.  A Longitudinal Study of Maternal Dose Response to Low Molecular Weight Heparin in Pregnancy , 2003, Obstetrics and gynecology.

[81]  C. Ris-Stalpers,et al.  Accuracy of circulating placental growth factor, vascular endothelial growth factor, soluble fms‐like tyrosine kinase 1 and soluble endoglin in the prediction of pre‐eclampsia: a systematic review and meta‐analysis , 2012, BJOG : an international journal of obstetrics and gynaecology.

[82]  I. Bruce,et al.  Decreased live births in women with systemic lupus erythematosus , 2011, Arthritis care & research.

[83]  Mimi Y Kim,et al.  Evaluation of fetuses in a study of intravenous immunoglobulin as preventive therapy for congenital heart block: Results of a multicenter, prospective, open-label clinical trial. , 2010, Arthritis and rheumatism.

[84]  L. Jara,et al.  Impact of previous lupus nephritis on maternal and fetal outcomes during pregnancy , 2012, Clinical Rheumatology.

[85]  C. Hom,et al.  Systematic review of hydroxychloroquine use in pregnant patients with autoimmune diseases , 2009, Pediatric rheumatology online journal.

[86]  G. Hughes,et al.  Increased rate of lupus flare during pregnancy and the puerperium: a prospective study of 78 pregnancies. , 1996, British journal of rheumatology.

[87]  K. Michaud,et al.  Effects of infertility, pregnancy loss, and patient concerns on family size of women with rheumatoid arthritis and systemic lupus erythematosus , 2012, Arthritis care & research.

[88]  H. Sørensen,et al.  Risk of adverse birth outcome and miscarriage in pregnant users of non-steroidal anti-inflammatory drugs: population based observational study and case-control study , 2001, BMJ : British Medical Journal.

[89]  J. Smallhorn,et al.  Transplacental Fetal Treatment Improves the Outcome of Prenatally Diagnosed Complete Atrioventricular Block Without Structural Heart Disease , 2004, Circulation.

[90]  Lindheimer,et al.  American Society of Hypertension. ASH Position Paper: Hypertension in Pregnancy , 2009 .

[91]  A. Tincani,et al.  Pregnancy outcome in 100 women with autoimmune diseases and anti-Ro/SSA antibodies: a prospective controlled study , 2002, Lupus.

[92]  R. Xu,et al.  Pregnancy outcome in women exposed to leflunomide before or during pregnancy. , 2012, Arthritis and rheumatism.

[93]  L. Magder,et al.  The Clinical Utility of Measuring Complement and Anti-dsDNA Antibodies During Pregnancy in Patients with Systemic Lupus Erythematosus , 2011, The Journal of Rheumatology.

[94]  J. Kingdom,et al.  The importance of the level of maternal anti-Ro/SSA antibodies as a prognostic marker of the development of cardiac neonatal lupus erythematosus a prospective study of 186 antibody-exposed fetuses and infants. , 2010, Journal of the American College of Cardiology.

[95]  L. Magder,et al.  Hydroxychloroquine in lupus pregnancy. , 2006, Arthritis and rheumatism.

[96]  Mimi Y. Kim,et al.  Prediction of adverse pregnancy outcome by the presence of lupus anticoagulant, but not anticardiolipin antibody, in patients with antiphospholipid antibodies. , 2012, Arthritis and rheumatism.

[97]  Mimi Y. Kim,et al.  Utility of Cardiac Monitoring in Fetuses at Risk for Congenital Heart Block: The PR Interval and Dexamethasone Evaluation (PRIDE) Prospective Study , 2008, Circulation.

[98]  B. Hammond Lupus , 2004 .

[99]  M. Petri,et al.  Frequency of lupus flare in pregnancy. The Hopkins Lupus Pregnancy Center experience. , 2010, Arthritis and rheumatism.

[100]  Robert C. Wolpert,et al.  A Review of the , 1985 .

[101]  F. Petraglia,et al.  High Levels of Maternal Serum IL‐17 and Activin A in Pregnant Women Affected by Systemic Lupus Erythematosus , 2011, American journal of reproductive immunology.

[102]  G. Koren,et al.  Nonsteroidal Antiinflammatory Drugs During Third Trimester and the Risk of Premature Closure of the Ductus Arteriosus: A Meta-Analysis , 2006, The Annals of pharmacotherapy.

[103]  K. Hongo,et al.  A case report and review of the literature , 2006, Journal of Neuro-Oncology.

[104]  M. Petri,et al.  Management of antiphospholipid syndrome in pregnancy. , 2006, Rheumatic diseases clinics of North America.

[105]  J. Sánchez-Guerrero,et al.  A trial of contraceptive methods in women with systemic lupus erythematosus. , 2005, The New England journal of medicine.

[106]  E. Jaeggi,et al.  Non‐Cardiac Manifestations of Neonatal Lupus Erythematosus , 2010, Scandinavian journal of immunology.

[107]  D. Friedman,et al.  Association of the idiotype:antiidiotype antibody ratio with the efficacy of intravenous immunoglobulin treatment for the prevention of recurrent autoimmune-associated congenital heart block. , 2011, Arthritis and rheumatism.

[108]  M. Petri The Hopkins Lupus Pregnancy Center: ten key issues in management. , 2007, Rheumatic diseases clinics of North America.

[109]  L. Trupin,et al.  Contraceptive counseling and use among women with systemic lupus erythematosus: A gap in health care quality? , 2010, Arthritis care & research.

[110]  J. Douketis,et al.  The use of antiplatelet therapy in the outpatient setting: Canadian Cardiovascular Society guidelines. , 2011, The Canadian journal of cardiology.

[111]  P. Meroni,et al.  Anti-phospholipid antibody mediated fetal loss: still an open question from a pathogenic point of view , 2010, Lupus.

[112]  D. Mevorach,et al.  Early Diagnosis and Treatment of Atrioventricular Block in the Fetus Exposed to Maternal Anti-SSA/Ro-SSB/La Antibodies: A Prospective, Observational, Fetal Kinetocardiogram–Based Study , 2009, Circulation.

[113]  M. Petri Prospective study of systemic lupus erythematosus pregnancies , 2004, Lupus.

[114]  R. Kaaja,et al.  Prevention of recurrence of congenital heart block with intravenous immunoglobulin and corticosteroid therapy: comment on the editorial by Buyon et al. , 2003, Arthritis and rheumatism.

[115]  C. Gordon,et al.  Update on safety during pregnancy of biological agents and some immunosuppressive anti-rheumatic drugs. , 2008, Rheumatology.

[116]  D. Balaban,et al.  Repeated fetal losses associated with antiphospholipid antibodies: a collaborative randomized trial comparing prednisone with low-dose heparin treatment. , 1992, American journal of obstetrics and gynecology.

[117]  K. Bailey,et al.  Maternal and foetal outcomes in pregnant patients with active lupus nephritis , 2009, Lupus.